Literature DB >> 17268118

Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome.

Olivera Dimitrijević1, Blagica Djorić Stojcevski, Svetlana Ignjatović, Nada Majkić Singh.   

Abstract

Systemic markers of inflammation are considered reliable predictors of future coronary events in patients with acute myocardial infarction (AMI). The aim of this study was to evaluate the prognostic relevance of serial C-reactive protein (CRP) measurements in patients with ST-elevation AMI (STEMI) on one-year outcome. In 31 patients with STEMI, serial measurements of CRP were obtained, and for each patient, the following values were determined: (i) values at admission, up to 12 hours after symptom onset, (ii) maximal values obtained 24-72 hours after symptom onset (early acute values), and (iii) late acute values (96-120 hours after symptom onset). The combined endpoint was any new cardiovascular event, including death. Early and late acute CRP levels were the only parameters found to be significantly higher in patients with an adverse outcome than in patients with a good outcome. A significantly higher rate of endpoint events was found in patients with elevated early (Hazard ratio [HR] 5.54, 95%CI 2.05-25.40; P = 0.007) and late acute CRP (HR 9.01, 95% CI 1.66-19.56; P = 0.005). Multiple logistic regression analysis identified only early acute CRP as an independent predictor of an unfavorable outcome (Odds ratio 8.00, 95%CI 1.15-55.60; P = 0.04), after adjustment for established risk factors. CRP level measured 24-72 hours after symptom onset is an independent predictor of one-year outcome in patients with STEMI. Values obtained later in the setting of STEMI do not add further prognostic information. CRP at admission is not related to long-term prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17268118     DOI: 10.1536/ihj.47.833

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  7 in total

1.  C-reactive protein velocity and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention.

Authors:  David Zahler; Keren-Lee Rozenfeld; Maya Stein; Assi Milwidsky; Shlomo Berliner; Shmuel Banai; Yaron Arbel; Yacov Shacham
Journal:  J Nephrol       Date:  2019-01-31       Impact factor: 3.902

2.  Prediction of Infarct Transmurality From C-Reactive Protein Level and Mean Platelet Volume in Patients With ST-Elevation Myocardial Infarction: Comparison of the Predictive Values of Cardiac Enzymes.

Authors:  DongHun Kim; Dong-Hyun Choi; Bo-Bae Kim; Seo-Won Choi; Keun Ho Park; Heesang Song
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

Review 3.  Inflammatory processes in cardiovascular disease: a route to targeted therapies.

Authors:  Neil Ruparelia; Joshua T Chai; Edward A Fisher; Robin P Choudhury
Journal:  Nat Rev Cardiol       Date:  2016-12-01       Impact factor: 32.419

4.  Predictors of coronary intervention-related myocardial infarction in stable angina patients pre-treated with statins.

Authors:  Josef Veselka; Petr Hájek; Martin Malý; David Zemánek; Radka Adlová; Pavol Tomašov; Lucie Martinkovičová; David Tesař; Pavel Cervinka
Journal:  Arch Med Sci       Date:  2011-03-08       Impact factor: 3.318

Review 5.  Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation.

Authors:  Malte Kircher; Constantin Lapa
Journal:  Curr Cardiovasc Imaging Rep       Date:  2017-02-10

Review 6.  Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations.

Authors:  Stefan Kayser; Patrizia Brunner; Katharina Althaus; Johannes Dorst; Ahmed Sheriff
Journal:  J Clin Med       Date:  2020-09-12       Impact factor: 4.241

Review 7.  [CRP apheresis in acute myocardial infarction and COVID-19].

Authors:  Michael Buerke; Ahmed Sheriff; Christoph D Garlichs
Journal:  Med Klin Intensivmed Notfmed       Date:  2022-03-25       Impact factor: 1.552

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.